CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues
Total revenues	$ 5,262,752	$ 4,165,706
Total cost of revenues	2,885,069	3,056,568
Gross profit	2,377,683	1,109,138
Operating expenses:
Selling, general and administrative	2,625,357	4,735,619
Research and development	971,304	1,080,096
Total operating expenses	3,596,661	5,815,715
LOSS FROM OPERATIONS	(1,218,978)	(4,706,577)
Interest income, net	3,686	273
Unrealized loss on change in fair value of warrants classified as a liability	(2,637,800)	0
Other income (expense), net	8,846	(14,607)
Loss before provision for income taxes	(3,844,246)	(4,720,911)
Provision for income taxes	0	0
NET LOSS	(3,844,246)	(4,720,911)
Less: Net loss (income) attributable to noncontrolling interest	874	(855)
NET LOSS attributable to Applied DNA Sciences, Inc.	$ (3,843,372)	$ (4,721,766)
Net loss per share attributable to common stockholders - basic	$ (0.30)	$ (0.63)
Net loss per share attributable to common stockholders - diluted	$ (0.30)	$ (0.48)
Weighted average shares outstanding - basic	12,908,520	7,486,120
Weighted average shares outstanding - diluted	12,908,520	7,486,120
Product revenues
Revenues
Total revenues	$ 516,396	$ 826,311
Total cost of revenues	365,378	434,929
Service revenues
Revenues
Total revenues	232,061	139,273
Clinical laboratory service revenues
Revenues
Total revenues	4,514,295	3,200,122
Total cost of revenues	$ 2,519,691	$ 2,621,639